# Cardioprotective mechanism of ω-3 fatty acid icosapent ethyl (IPE) in cardiomyocytes: role in high glucose and shear stress-induced mechano-transduction dysregulation

**Authors:** Ada Pesapane, Lucia Scisciola, Manuela Giovanna Basilicata, Rosaria Anna Fontanella, Nunzia Balzano, Annalisa Capuano, Asad Zia, Maryam Arshad, Zeeshan Ulfat, Giovanni Tortorella, Ludovica Vittoria Marfella, Alberta Maria Maddalena Palazzo, Giuseppe Signoriello, Celestino Sardu, Giuseppe Paolisso, Michelangela Barbieri

PMC · DOI: 10.1186/s12933-025-03033-8 · 2025-12-13

## TL;DR

This study shows that icosapent ethyl protects heart cells from damage caused by high glucose and turbulent blood flow by reducing inflammation and stress.

## Contribution

The study reveals a novel mechanism by which icosapent ethyl modulates mechano-transduction and inflammation in heart cells under metabolic and hemodynamic stress.

## Key findings

- IPE reduces YAP/TAZ pathway activation caused by high glucose in cardiomyocytes.
- IPE mitigates inflammation, oxidative stress, and metabolic changes in high glucose and shear stress conditions.
- IPE restores upstream regulators of YAP/TAZ and reduces pro-inflammatory pathways in disturbed flow models.

## Abstract

Omega-3 fatty acids (FAs) are long-chain fatty acids that have shown cardioprotective effects through lipid lowering, anti-inflammatory, and membrane-stabilizing properties. In this study we investigated the molecular mechanism underlying the cardioprotective effects of icosapent ethyl (IPE), an ethyl ester of omega-3 fatty (EPA), focusing on its role on mechano-transduction, a process linking cardiac contractility to intracellular signaling, that becomes dysregulated in hyperglycaemia or disturbed blood flow, both major contributors to cardiovascular diseases.

We conducted in vivo meta-analyses to assess the beneficial effects of omega-3 fatty acids on cardiac contractility and inflammation in patients with cardiovascular and cardiometabolic diseases. We investigated the effects of IPE on mechano-transduction, assessing the activation of the YAP/TAZ signalling pathway, in cardiomyocyte cells AC16 exposed to normal (NG) or high glucose (HG) conditions. We defined the role of IPE against hyperglycaemia-induced inflammation, oxidative stress, metabolism, and apoptosis by evaluating key biomarkers by Western Blot and Real-time PCR. We evaluated IPE’s impact on YAP/TAZ activation and on gene expression and protein levels of primary markers related to oxidative stress, inflammation, and metabolism in a dynamic flow model of AC16 cardiomyocytes, to mimic in vivo shear stress.

In vivo meta-analyses showed a significant increase of left ventricular ejection fraction (LVEF%) (mean: 0.5, 95% CI: 0.1–0.9) and a significant reduction of inflammatory markers (mean:  − 1.24, 95% CI: 2.05–0.44) in patients treated with omega-3. IPE treatment reduced the activation of YAP/TAZ pathway induced by HG exposure in AC16 cells. IPE partially reversed HG-induced changes in markers of inflammation, oxidative stress, metabolism and apoptosis (p < 0.05). Similarly, in a dynamic model of shear stress, IPE treatment mitigated the turbulent flow-mediated changes in YAP/TAZ pathway, inflammation, oxidative stress and metabolism.

Our results demonstrate a cardioprotective role of IPE through modulation of hyperglycaemia-induced mechano-transduction dysregulation, inflammation, and oxidative stress. Additionally, our results on a shear stress model showing that IPE restores upstream regulators of YAP/TAZ and reduces disturbed flow-induced activation of pro-inflammatory pathways, suggest that IPE may exert a therapeutic effect on cardiovascular disorders associated with disturbed blood flow and hemodynamic stress.

The online version contains supplementary material available at 10.1186/s12933-025-03033-8.

## Linked entities

- **Proteins:** YAP1 (Yes1 associated transcriptional regulator), TAFAZZIN (tafazzin, phospholipid-lysophospholipid transacylase)
- **Chemicals:** icosapent ethyl (PubChem CID 9831415), omega-3 fatty acids (PubChem CID 56842239), EPA (PubChem CID 446284)

## Full-text entities

- **Genes:** YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413] {aka COB1, YAP, YAP-1, YAP2, YAP65, YKI}, TAFAZZIN (tafazzin, phospholipid-lysophospholipid transacylase) [NCBI Gene 6901] {aka BTHS, CMD3A, EFE, EFE2, G4.5, LVNCX}
- **Diseases:** cardiovascular and cardiometabolic diseases (MESH:D002318), inflammation (MESH:D007249)
- **Chemicals:** glucose (MESH:D005947), IPE (MESH:C035276), ethyl ester (MESH:C465446), lipid (MESH:D008055), Omega-3 fatty acids (MESH:D015525), FAs (MESH:D005227), -chain fatty acids (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12805760/full.md

---
Source: https://tomesphere.com/paper/PMC12805760